Oxford, UK - 16 January 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, and its collaborative partners in the field of avian transgenics, Viragen, Inc. (AMEX: VRA) and Roslin Institute, today announced that the Proceedings of the National Academy of Sciences of the United States of America (PNAS), a leading scientific journal, has published an article profiling the avian transgenic (OVA™) system’s ability to express two therapeutic proteins in the whites of eggs of transgenic hens. The OVA™ System is being developed as a novel, large-scale biomanufacturing alternative, capable of cost-effectively expressing many types of therapeutic proteins.
